News & Updates

Detectable EGFRm in plasma ctDNA prior to treatment may define a subgroup of patients with advanced EGFRm NSCLC who would derive the most benefit from the addition of chemo to 1L osimertinib, according to an exploratory analysis of FLAURA2 presented at AACR 2024

A recent study has found an “unacceptably low” compliance of follow-up following abnormal human papillomavirus (HPV) tests among women in Singapore.

The novel endoscopic ultrasound (EUS)-guided gastroenterostomy (GE) is effective in patients with either a malignant or a benign disease, reports a study. In addition, adverse events are similar in both groups.

The combination of avelumab and cisplatin-based chemotherapy as neoadjuvant therapy for MIUC yields high OS and EFS rates at both 1 and 3 years, according to the survival data from the dual-cohort, phase II AURA trial presented at ASCO 2024

Vaginal estrogen therapy may be safely used to treat genitourinary symptoms in early-stage breast cancer patients with HR-negative tumours and in those concurrently treated with tamoxifen, according to the results of a target trial emulation. However, its use may be detrimental to disease-free survival (DFS) outcomes in patients receiving aromatase inhibitors.

TG4050, a novel viral-based personalized cancer vaccine, showed promise in a phase I trial presented during a late-breaking poster presentation at AACR 2024. The investigational vaccine induced polyepitopic immune responses against private neoantigens in resected HPV-negative head and neck squamous cell cancer (HNSCC).

Working out can improve sexual function as well as reduce endocrine sexual symptoms in patients with metastatic breast cancer (mBC), according to data from the PREFERABLE-EFFECT trial.